



Human Chemistry, Human Solutions

NEWS RELEASE

Teijin to invest in U.S. Venture-capital Fund

Tokyo, Japan, April 6, 2020 --- [Teijin Limited](#) announced today that it will invest up to approximately 90 million U.S. dollars in the Medtech Convergence Fund (MCF), a healthcare venture-capital fund managed by SV Health Investors.

SV Health Investors has partnered with the senior members of Norwich Ventures to create this new fund and build the portfolio.

SV Health Investors and Norwich Ventures have excellent reputations for investing in and nurturing Medtech startups. The MCF team will leverage their decades of operating and investment experience to provide entrepreneurs with the financial support and strategic guidance necessary for building a successful business.

Through investment and collaboration with its new partners, Teijin aims to acquire new technologies and develop new businesses in the healthcare field. In particular, MCF will focus on regulated medical devices in less-intensive care settings, including in the home.

Teijin's decision to invest in the fund reflects the company's vision of developing disruptive, cost-saving healthcare solutions, which closely matches the vision of the MCF team.

Teijin's medium- to long-term strategy for its healthcare business, as defined in its Medium-Term Management Plan for 2020-2022 "ALWAYS EVOLVING", envisions the development of community-based comprehensive healthcare solutions that will leverage the company's expertise in pharmaceutical and home-healthcare businesses. Teijin will focus on innovative healthcare products and services, including individual treatments, to enable people to live healthier, happier and more fulfilling lives.

Medtech Convergence Fund

Fund Size	90 million U.S. dollars (including the GP commitment)
Fund Partners	General partner: Medtech Convergence GP, LLC Limited partner: Teijin Limited
Headquarters	Boston, Massachusetts
Investment field	Medical devices and services in healthcare field
Investment targets	Early stage companies
Investment locations	Primarily U.S., Europe and Israel

Teijin will share employees with the fund to strengthen long-term collaboration aimed at development of healthcare businesses in international markets. In addition, through participation in company incubation activities with its new partners, Teijin aims to stimulate its own research and development of medical devices and services based on novel innovation models.

Healthcare solutions comprising products, services and digital technologies are becoming increasingly vital worldwide, including in Japan where the population is aging rapidly. Teijin is committed to providing superior products and specialized services to enhance the quality of life of patients worldwide.

About the Medtech Convergence Fund

The Medtech Convergence Fund (MCF) is a seed and early-stage venture capital fund committed to helping entrepreneurs, healthcare professionals and inventors build innovative medical technology companies. Our fund strategy is focused on the increasing convergence of medical technology with software, telecommunications, and new service models to create solutions to some of the most significant health challenges. MCF's mission is to invest in therapeutic and monitoring technologies that offer superior patient outcomes while enabling better healthcare efficiency. The MCF team leverages decades of medical device investing and operating experience to help entrepreneurs succeed from the earliest phases of product development.

To learn more visit <https://www.medtechconvergence.com>

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has over 170 companies and around 20,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY888.6 billion (USD 8.1 billion) and total assets of JPY 1020.7 billion (USD 9.3 billion) in the fiscal year ending March 31, 2019.

Press Contact

Corporate Communications

Teijin Limited

pr@teijin.co.jp